Sunday, 22 April 2018 - 19:31
  • it
  • de
  • en
  • fr


Besponsa (leukemia) approved in Europe

The European Commission adopted a positive opinion on Pfizer’s Besponsa (inotuzumab ozogamicin) as monotherapy for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Adults allowed to undergo a treatment with Besponsa should have failed treatment…

Rocket (leukemia) trial halted again, Juno’s shares fall 30%

Juno announced it halted the Phase II Rocket trial for JCAR015, a CAR-T therapy targeting acute lymphoblastic leukemia, following the death of two patients due to brain tissue swelling. This is the second time Juno has suspended the Rocket study,…